ghk-cu peptide fda approved for Sale | Tripeptide-1 | 3rd-Party Tested GHK-CU - Research Peptide -
Description
JBSNF-000088 binds to the active site on NNMT and leads to the demethylation of SAM to SAH ( JBSNF-000028 (Ruf et al., 2022) and JBSNF-000088 ( JBSNF-000265 was discovered through Structure-Activity Relationship (SAR) studies (Ruf et al., 2018) as a compound that binds to NNMT in a manner similar to that of NAM
Patients with Hepatic Impairment Hepatic impairment does not impact the pharmacokinetics of tirzepatide
Disease-modifying strategies for Parkinsons disease
We transmit your request to a vetted pharmacy partner
